Literature DB >> 19188574

Incidence and remaining lifetime risk of Parkinson disease in advanced age.

Jane A Driver1, Giancarlo Logroscino, J Michael Gaziano, Tobias Kurth.   

Abstract

OBJECTIVE: To estimate the incidence and lifetime risk (LTR) of Parkinson disease (PD) in a large cohort of men.
BACKGROUND: Age is the strongest risk factor for PD, but whether its incidence continues to increase after age 80 years remains unclear.
METHODS: Prospective cohort of 21,970 US male physicians aged 40-84 years at baseline who did not report PD before study entry. Participants self-reported PD on yearly follow-up questionnaires, and all deaths were confirmed. We calculated incidence rates and cumulative incidence using a modified Kaplan-Meier analysis. LTR was estimated by adjusting cumulative incidence for competing risks of death.
RESULTS: Five hundred sixty-three cases of PD were identified over 23 years of follow-up. The crude incidence rate of PD was 121 cases/100,000 person-years. Age-specific incidence rates increased sharply beginning at age 60 years, peaked in those aged 85-89 years, and declined beginning at age 90 years. Cumulative incidence substantially overestimated the long-term risk of PD, particularly in those aged 80 years and older. Cumulative incidence was 9.9% (95% confidence interval [CI] 8.48%-11.30%) from ages 45 to 100 years, whereas LTR for the same period was 6.7% (95% CI 6.01%-7.43%). The incidence and LTR of PD decreased with increasing exposure to smoking.
CONCLUSIONS: Our study provides evidence that the incidence of Parkinson disease (PD) in men increases through age 89 years. Whether the subsequent decline represents a true decrease in risk remains to be established. A history of smoking substantially decreased the incidence and lifetime risk of PD. Incidence studies that do not adjust for competing risks of death may overestimate the true risk of PD in the elderly.

Entities:  

Mesh:

Year:  2009        PMID: 19188574      PMCID: PMC2676726          DOI: 10.1212/01.wnl.0000341769.50075.bb

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  31 in total

1.  The frequency of idiopathic Parkinson's disease by age, ethnic group, and sex in northern Manhattan, 1988-1993.

Authors:  R Mayeux; K Marder; L J Cote; J Denaro; N Hemenegildo; H Mejia; M X Tang; R Lantigua; D Wilder; B Gurland
Journal:  Am J Epidemiol       Date:  1995-10-15       Impact factor: 4.897

2.  How common are the "common" neurologic disorders?

Authors:  D Hirtz; D J Thurman; K Gwinn-Hardy; M Mohamed; A R Chaudhuri; R Zalutsky
Journal:  Neurology       Date:  2007-01-30       Impact factor: 9.910

3.  Final report on the aspirin component of the ongoing Physicians' Health Study.

Authors: 
Journal:  N Engl J Med       Date:  1989-07-20       Impact factor: 91.245

4.  Incidence of parkinsonism and Parkinson disease in a general population: the Rotterdam Study.

Authors:  L M L de Lau; P C L M Giesbergen; M C de Rijk; A Hofman; P J Koudstaal; M M B Breteler
Journal:  Neurology       Date:  2004-10-12       Impact factor: 9.910

5.  Prospective case-control study of nonfatal cancer preceding the diagnosis of Parkinson's disease.

Authors:  Jane A Driver; Tobias Kurth; Julie E Buring; J Michael Gaziano; Giancarlo Logroscino
Journal:  Cancer Causes Control       Date:  2007-06-12       Impact factor: 2.506

6.  Parkinson's disease in Ferrara, Italy, 1967 through 1987.

Authors:  E Granieri; M Carreras; I Casetta; V Govoni; M R Tola; E Paolino; V C Monetti; P De Bastiani
Journal:  Arch Neurol       Date:  1991-08

7.  Cancer incidence: life table risk versus cumulative risk.

Authors:  L J Schouten; H Straatman; L A Kiemeney; A L Verbeek
Journal:  J Epidemiol Community Health       Date:  1994-12       Impact factor: 3.710

8.  Prevalence of parkinsonian signs and associated mortality in a community population of older people.

Authors:  D A Bennett; L A Beckett; A M Murray; K M Shannon; C G Goetz; D M Pilgrim; D A Evans
Journal:  N Engl J Med       Date:  1996-01-11       Impact factor: 91.245

9.  Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease.

Authors:  C H Hennekens; J E Buring; J E Manson; M Stampfer; B Rosner; N R Cook; C Belanger; F LaMotte; J M Gaziano; P M Ridker; W Willett; R Peto
Journal:  N Engl J Med       Date:  1996-05-02       Impact factor: 91.245

10.  Heart disease and stroke statistics--2008 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee.

Authors:  Wayne Rosamond; Katherine Flegal; Karen Furie; Alan Go; Kurt Greenlund; Nancy Haase; Susan M Hailpern; Michael Ho; Virginia Howard; Brett Kissela; Bret Kissela; Steven Kittner; Donald Lloyd-Jones; Mary McDermott; James Meigs; Claudia Moy; Graham Nichol; Christopher O'Donnell; Veronique Roger; Paul Sorlie; Julia Steinberger; Thomas Thom; Matt Wilson; Yuling Hong
Journal:  Circulation       Date:  2007-12-17       Impact factor: 29.690

View more
  77 in total

Review 1.  Axon degeneration in Parkinson's disease.

Authors:  Robert E Burke; Karen O'Malley
Journal:  Exp Neurol       Date:  2012-01-18       Impact factor: 5.330

2.  Mitochondrial clearance and maturation of autophagosomes are compromised in LRRK2 G2019S familial Parkinson's disease patient fibroblasts.

Authors:  Joanna A Korecka; Ria Thomas; Dan P Christensen; Anthony J Hinrich; Eliza J Ferrari; Simon A Levy; Michelle L Hastings; Penelope J Hallett; Ole Isacson
Journal:  Hum Mol Genet       Date:  2019-10-01       Impact factor: 6.150

3.  Factors to Consider in the Selection of Dopamine Agonists for Older Persons with Parkinson's Disease.

Authors:  Mark Dominic Latt; Simon Lewis; Olfat Zekry; Victor S C Fung
Journal:  Drugs Aging       Date:  2019-03       Impact factor: 3.923

4.  Cerebrovascular disease pathology and parkinsonian signs in old age.

Authors:  Aron S Buchman; Sue E Leurgans; Sukriti Nag; David A Bennett; Julie A Schneider
Journal:  Stroke       Date:  2011-09-01       Impact factor: 7.914

Review 5.  Are sleep disturbances preclinical markers of Parkinson's disease?

Authors:  Altair B dos Santos; Kristi A Kohlmeier; George E Barreto
Journal:  Neurochem Res       Date:  2014-11-30       Impact factor: 3.996

6.  Motor and non-motor symptoms in old-age onset Parkinson's disease patients.

Authors:  Marcelo D Mendonça; Tania Lampreia; Rita Miguel; André Caetano; Raquel Barbosa; Paulo Bugalho
Journal:  J Neural Transm (Vienna)       Date:  2017-03-17       Impact factor: 3.575

7.  Estimating risk for developing epilepsy: a population-based study in Rochester, Minnesota.

Authors:  D C Hesdorffer; G Logroscino; E K T Benn; N Katri; G Cascino; W A Hauser
Journal:  Neurology       Date:  2011-01-04       Impact factor: 9.910

Review 8.  [Parkinson's disease in the elderly].

Authors:  Rüdiger Lange; Frank Erbguth
Journal:  Z Gerontol Geriatr       Date:  2017-07-19       Impact factor: 1.281

9.  Negative Conditioning of Mitochondrial Dysfunction in Age-related Neurodegenerative Diseases.

Authors:  Sharmelee Selvaraji; Luting Poh; Venkateswaran Natarajan; Karthik Mallilankaraman; Thiruma V Arumugam
Journal:  Cond Med       Date:  2019-02

10.  Relation between modifiable lifestyle factors and lifetime risk of heart failure.

Authors:  Luc Djoussé; Jane A Driver; J Michael Gaziano
Journal:  JAMA       Date:  2009-07-22       Impact factor: 56.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.